Phase I study of topotecan and cisplatin in patients with small cell lung cancer

Yukito Ichinose, Takashi Seto, Yutaka Nishiwaki, Katsuyuki Kiura, Hiroshi Sakai, Akira Yokoyama, Yoshihiko Segawa, Masahiro Ando, Koshiro Watanabe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: A single-agent topotecan has an indication for the treatment of small cell lung cancer in Japan. Previous studies demonstrated that topotecan combined with a platinum agent could provide additional antitumor efficacy. This study was to find the recommended dose of topotecan in combination with cisplatin and preferred administration sequence in untreated patients with extensive disease small cell lung cancer for Phase II study. Methods: Patients received topotecan as a 30 min infusion for 5 days in escalating doses (starting at 0.5 mg/m2/day), and cisplatin at a fixed dose of 60 mg/m2, 3 weeks cycle. This study employed the following stages: cisplatin was given before topotecan on day 1 to previously treated patients (Stage 1). After the maximum-tolerated dose level was achieved, the same schedule was applied for untreated patients (Stage 2). Subsequently, cisplatin was given after topotecan on day 5 to untreated patients (Stage 3). The recommended doses of cisplatin on day 1 and 5 schedules were estimated by considering results obtained from Stages 2 and 3, respectively. Results: A total of 34 patients were enrolled. The maximum-tolerated doses in Stages 1-3 were estimated at 0.65, 0.65, and 1.4 mg/m2, respectively. The recommended doses of cisplatin on day 1 and 5 schedules in untreated patients were determined at 0.65 and 1.0 mg/m2, respectively. The major toxicity in this combination was hematological events. Conclusions: For treatment-naive patients, the combined use of 0.65/60 mg/m2 topotecan/cisplatin with cisplatin on day 1 schedule or 1.0/60 mg/m2 topotecan/cisplatin with cisplatin on day 5 schedule is recommended for Phase II study.

Original languageEnglish
Pages (from-to)197-203
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume41
Issue number2
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Topotecan
Small Cell Lung Carcinoma
Cisplatin
Appointments and Schedules
Maximum Tolerated Dose
Platinum
Japan

Keywords

  • Cisplatin
  • Combination chemotherapy
  • Small cell lung cancer
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Ichinose, Y., Seto, T., Nishiwaki, Y., Kiura, K., Sakai, H., Yokoyama, A., ... Watanabe, K. (2011). Phase I study of topotecan and cisplatin in patients with small cell lung cancer. Japanese Journal of Clinical Oncology, 41(2), 197-203. https://doi.org/10.1093/jjco/hyq177

Phase I study of topotecan and cisplatin in patients with small cell lung cancer. / Ichinose, Yukito; Seto, Takashi; Nishiwaki, Yutaka; Kiura, Katsuyuki; Sakai, Hiroshi; Yokoyama, Akira; Segawa, Yoshihiko; Ando, Masahiro; Watanabe, Koshiro.

In: Japanese Journal of Clinical Oncology, Vol. 41, No. 2, 02.2011, p. 197-203.

Research output: Contribution to journalArticle

Ichinose, Y, Seto, T, Nishiwaki, Y, Kiura, K, Sakai, H, Yokoyama, A, Segawa, Y, Ando, M & Watanabe, K 2011, 'Phase I study of topotecan and cisplatin in patients with small cell lung cancer', Japanese Journal of Clinical Oncology, vol. 41, no. 2, pp. 197-203. https://doi.org/10.1093/jjco/hyq177
Ichinose, Yukito ; Seto, Takashi ; Nishiwaki, Yutaka ; Kiura, Katsuyuki ; Sakai, Hiroshi ; Yokoyama, Akira ; Segawa, Yoshihiko ; Ando, Masahiro ; Watanabe, Koshiro. / Phase I study of topotecan and cisplatin in patients with small cell lung cancer. In: Japanese Journal of Clinical Oncology. 2011 ; Vol. 41, No. 2. pp. 197-203.
@article{a39b8e2773414638855700d4c2b25036,
title = "Phase I study of topotecan and cisplatin in patients with small cell lung cancer",
abstract = "Objective: A single-agent topotecan has an indication for the treatment of small cell lung cancer in Japan. Previous studies demonstrated that topotecan combined with a platinum agent could provide additional antitumor efficacy. This study was to find the recommended dose of topotecan in combination with cisplatin and preferred administration sequence in untreated patients with extensive disease small cell lung cancer for Phase II study. Methods: Patients received topotecan as a 30 min infusion for 5 days in escalating doses (starting at 0.5 mg/m2/day), and cisplatin at a fixed dose of 60 mg/m2, 3 weeks cycle. This study employed the following stages: cisplatin was given before topotecan on day 1 to previously treated patients (Stage 1). After the maximum-tolerated dose level was achieved, the same schedule was applied for untreated patients (Stage 2). Subsequently, cisplatin was given after topotecan on day 5 to untreated patients (Stage 3). The recommended doses of cisplatin on day 1 and 5 schedules were estimated by considering results obtained from Stages 2 and 3, respectively. Results: A total of 34 patients were enrolled. The maximum-tolerated doses in Stages 1-3 were estimated at 0.65, 0.65, and 1.4 mg/m2, respectively. The recommended doses of cisplatin on day 1 and 5 schedules in untreated patients were determined at 0.65 and 1.0 mg/m2, respectively. The major toxicity in this combination was hematological events. Conclusions: For treatment-naive patients, the combined use of 0.65/60 mg/m2 topotecan/cisplatin with cisplatin on day 1 schedule or 1.0/60 mg/m2 topotecan/cisplatin with cisplatin on day 5 schedule is recommended for Phase II study.",
keywords = "Cisplatin, Combination chemotherapy, Small cell lung cancer, Topotecan",
author = "Yukito Ichinose and Takashi Seto and Yutaka Nishiwaki and Katsuyuki Kiura and Hiroshi Sakai and Akira Yokoyama and Yoshihiko Segawa and Masahiro Ando and Koshiro Watanabe",
year = "2011",
month = "2",
doi = "10.1093/jjco/hyq177",
language = "English",
volume = "41",
pages = "197--203",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Phase I study of topotecan and cisplatin in patients with small cell lung cancer

AU - Ichinose, Yukito

AU - Seto, Takashi

AU - Nishiwaki, Yutaka

AU - Kiura, Katsuyuki

AU - Sakai, Hiroshi

AU - Yokoyama, Akira

AU - Segawa, Yoshihiko

AU - Ando, Masahiro

AU - Watanabe, Koshiro

PY - 2011/2

Y1 - 2011/2

N2 - Objective: A single-agent topotecan has an indication for the treatment of small cell lung cancer in Japan. Previous studies demonstrated that topotecan combined with a platinum agent could provide additional antitumor efficacy. This study was to find the recommended dose of topotecan in combination with cisplatin and preferred administration sequence in untreated patients with extensive disease small cell lung cancer for Phase II study. Methods: Patients received topotecan as a 30 min infusion for 5 days in escalating doses (starting at 0.5 mg/m2/day), and cisplatin at a fixed dose of 60 mg/m2, 3 weeks cycle. This study employed the following stages: cisplatin was given before topotecan on day 1 to previously treated patients (Stage 1). After the maximum-tolerated dose level was achieved, the same schedule was applied for untreated patients (Stage 2). Subsequently, cisplatin was given after topotecan on day 5 to untreated patients (Stage 3). The recommended doses of cisplatin on day 1 and 5 schedules were estimated by considering results obtained from Stages 2 and 3, respectively. Results: A total of 34 patients were enrolled. The maximum-tolerated doses in Stages 1-3 were estimated at 0.65, 0.65, and 1.4 mg/m2, respectively. The recommended doses of cisplatin on day 1 and 5 schedules in untreated patients were determined at 0.65 and 1.0 mg/m2, respectively. The major toxicity in this combination was hematological events. Conclusions: For treatment-naive patients, the combined use of 0.65/60 mg/m2 topotecan/cisplatin with cisplatin on day 1 schedule or 1.0/60 mg/m2 topotecan/cisplatin with cisplatin on day 5 schedule is recommended for Phase II study.

AB - Objective: A single-agent topotecan has an indication for the treatment of small cell lung cancer in Japan. Previous studies demonstrated that topotecan combined with a platinum agent could provide additional antitumor efficacy. This study was to find the recommended dose of topotecan in combination with cisplatin and preferred administration sequence in untreated patients with extensive disease small cell lung cancer for Phase II study. Methods: Patients received topotecan as a 30 min infusion for 5 days in escalating doses (starting at 0.5 mg/m2/day), and cisplatin at a fixed dose of 60 mg/m2, 3 weeks cycle. This study employed the following stages: cisplatin was given before topotecan on day 1 to previously treated patients (Stage 1). After the maximum-tolerated dose level was achieved, the same schedule was applied for untreated patients (Stage 2). Subsequently, cisplatin was given after topotecan on day 5 to untreated patients (Stage 3). The recommended doses of cisplatin on day 1 and 5 schedules were estimated by considering results obtained from Stages 2 and 3, respectively. Results: A total of 34 patients were enrolled. The maximum-tolerated doses in Stages 1-3 were estimated at 0.65, 0.65, and 1.4 mg/m2, respectively. The recommended doses of cisplatin on day 1 and 5 schedules in untreated patients were determined at 0.65 and 1.0 mg/m2, respectively. The major toxicity in this combination was hematological events. Conclusions: For treatment-naive patients, the combined use of 0.65/60 mg/m2 topotecan/cisplatin with cisplatin on day 1 schedule or 1.0/60 mg/m2 topotecan/cisplatin with cisplatin on day 5 schedule is recommended for Phase II study.

KW - Cisplatin

KW - Combination chemotherapy

KW - Small cell lung cancer

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=79251628083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251628083&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq177

DO - 10.1093/jjco/hyq177

M3 - Article

C2 - 20937601

AN - SCOPUS:79251628083

VL - 41

SP - 197

EP - 203

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -